- Conditions
- Alzheimer Disease
- Interventions
- BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hepatic Impairment
- Interventions
- BPN14770
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • San Antonio, Texas
- Conditions
- Depression
- Interventions
- [C-11]T-1650, BPN14770
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder
- Interventions
- BPN14770, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 9 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Seattle, Washington
- Conditions
- Fragile X Syndrome
- Interventions
- zatolmilast, Placebo
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 9 Years to 18 Years · Male only
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 17
- States / cities
- Irvine, California • Orange, California • Sacramento, California + 14 more
- Conditions
- Alzheimer's Disease
- Interventions
- BPN14770, Placebo
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Kalamazoo, Michigan
- Conditions
- To Determine Brain Target Occupancy of BPN14770
- Interventions
- BPN14770, T2310
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Fragile X Syndrome
- Interventions
- Zatolmilast/ BPN14770
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 9 Years to 45 Years · Male only
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Irvine, California • Orange, California • Sacramento, California + 14 more
- Conditions
- Alzheimer's Disease
- Interventions
- BPN14770, Placebo
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 41
- States / cities
- Gilbert, Arizona • Bellflower, California • Costa Mesa, California + 31 more
- Conditions
- Renal Impairment
- Interventions
- BPN14770
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Fragile X Syndrome
- Interventions
- BPN14770/ zatolmilast, Placebo
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 17
- States / cities
- Irvine, California • Orange, California • Sacramento, California + 14 more
- Conditions
- Fragile X Syndrome, FXS, Fra(X) Syndrome
- Interventions
- BPN14770, Placebo
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy Participants
- Interventions
- Rosuvastatin, BPN14770
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Alzheimer's Disease
- Interventions
- BPN14770, Placebo
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 25 Years to 90 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Kalamazoo, Michigan